This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D80.8 | Synonyms: Kappa light chain deficiency, κ-chain deficiency, Immunoglobulin kappa chain deficiency
Immunoglobulin light chains first drew attention in 1956 through studies of Bence Jones protein. Later, as Porter (1958) and Edelman (1959) elucidated the four-chain structure of immunoglobulins (2 heavy chains + 2 light chains), the two types of light chain, kappa (κ) and lambda (λ), were distinguished.
Kappa light chain deficiency is a very rare primary immunodeficiency disease; Stavnezer-Nordgren et al. in 1984 first reported a patient with kappa light chain deficiency due to deletion of the IGKC gene. This patient was notable for producing immunoglobulins but constructing antibodies entirely with lambda light chains instead of kappa light chains.
The IGKC gene encoding the kappa light chain is located on chromosome 2 (2p11.2). Homozygous deletion of the IGKC gene has been identified as the main cause of kappa light chain deficiency. Such gene deletions rarely exist in the heterozygous state in the healthy population, and clinical symptoms can appear only with a homozygous deletion.
In Korea, kappa light chain deficiency is an extremely rare disease, with very few officially registered cases. There are almost no Korean literature reports, and it may be found among patients referred for abnormal serum immunoglobulin light chain ratios.
The main cause of kappa light chain deficiency is homozygous deletion of the IGKC gene encoding the kappa light chain constant region. This deletion makes synthesis of immunoglobulin kappa light chains completely impossible, and B cells construct antibodies using only lambda light chains.
In addition to IGKC gene deletion, point mutations or frameshift mutations can impair kappa light chain production. Defects in the gene rearrangement (V-J recombination) process may additionally be involved.
Even in the absence of kappa light chains, B cells produce immunoglobulins normally using lambda light chains. As a result, total immunoglobulin levels may not decrease, and no obvious abnormality may appear on serum immunoglobulin electrophoresis.
The IGKC gene is located on the short arm of chromosome 2 (2p11.2). The immunoglobulin kappa light chain gene cluster consists of V (variable), J (joining) and C (constant) segments. IGKC is a single constant region gene that encodes the entire human kappa light chain constant domain.
Heterozygous deletions of the IGKC gene are rarely found in the healthy population, and in this case there are no clinical symptoms. Kappa light chain deficiency occurs when there is a homozygous deletion (deletion on both parental chromosomes). It therefore follows an autosomal recessive inheritance pattern.
In normal serum, the kappa:lambda ratio is about 1.5~2:1. This means that antibodies with kappa light chains are produced about twice as much as antibodies with lambda light chains. In kappa light chain deficiency, this ratio becomes extremely low (kappa light chain = 0 or undetectable).
The frequency of heterozygous deletion of the IGKC gene varies by race, and the carrier frequency may be higher in certain populations. The ethnic epidemiology of kappa light chain deficiency has not yet been sufficiently studied.
Kappa light chain deficiency is an extremely rare immunodeficiency disease worldwide, and to date only a few dozen patients or fewer have been reported in the literature. Accurate estimation of prevalence is difficult because the number of patients is so small.
In the healthy population, the frequency of heterozygous IGKC deletion (deletion on only one chromosome) is estimated at about 1~3%, but it varies between studies. Homozygous deletion is very rare, keeping the incidence of kappa light chain deficiency low.
It occurs without sex differences, and the age at detection varies. Some cases are found in childhood due to recurrent infections, and some are discovered incidentally in adulthood due to immunoglobulin light chain abnormalities.
In Korea, officially registered patients with kappa light chain deficiency are very rare, and there are no systematic epidemiological data yet. It may be found incidentally when serum kappa/lambda light chain ratio testing is performed in clinical practice.
Normally, about 60% of B cells use kappa light chains and about 40% use lambda light chains to synthesize immunoglobulins. Kappa and lambda light chains are functionally similar and play an auxiliary role to the heavy chain in antigen binding.
In patients with homozygous deletion of the IGKC gene, B cells produce no kappa light chains at all, and all immunoglobulins are synthesized only in structures containing lambda light chains. Because antibodies using lambda light chains are structurally and functionally similar to those using kappa light chains, B cell development and the antibody response itself are maintained.
If kappa light chains cannot be used, the diversity of the antibody repertoire may theoretically be partially reduced. In practice, however, a sufficiently diverse antibody repertoire can be formed with lambda light chains alone, so in most patients clinically serious immunodeficiency may not appear.
If kappa light chain antibodies are predominantly produced in the immune response to certain specific antigens, protective immunity against those antigens may be insufficient in patients with kappa light chain deficiency. This hypothesis has not yet been sufficiently verified.
A considerable number of reported patients with kappa light chain deficiency are found only through abnormal immunoglobulin test findings without any particular clinical symptoms. When compensation through lambda light chains is sufficient, some remain asymptomatic.
Recurrent respiratory infections (otitis media, sinusitis, pneumonia) are reported in some patients. However, it is often unclear whether kappa light chain deficiency is the direct cause of the recurrent infections or whether they are due to other accompanying immune abnormalities.
On serum immunoglobulin electrophoresis, kappa light chains are not detected or are detected only in extremely small amounts. Total immunoglobulin levels may be normal or mildly decreased.
Associated autoimmune diseases have been reported in extremely rare cases, but a direct association with kappa light chain deficiency has not been established.
In most cases there are no specific physical examination findings. In patients with recurrent infections, findings of complications such as chronic sinusitis and bronchiectasis may appear.
The serum kappa/lambda light chain ratio is extremely low (0 or unmeasurable), and serum kappa free light chains are not detected. Total serum immunoglobulins (IgG, IgA, IgM) are mostly within the normal range, or immunoglobulins containing only lambda light chains are normal or increased.
Serum protein electrophoresis (SPEP) shows normal or mildly abnormal findings. On immunofixation electrophoresis, the kappa light chain band is absent and only lambda light chains are identified. B cell and T cell counts are generally normal.
On bone marrow or lymph node biopsy, a finding in which all plasma cells are lambda light chain positive with no kappa light chains may be observed.
Further evaluation is needed when an abnormal kappa/lambda ratio is found on serum free light chain (sFLC) testing or serum immunoglobulin light chain quantification during evaluation for primary immunodeficiency or screening for hematologic malignancy.
On serum immunofixation electrophoresis, a finding in which no kappa light chain band is detected at all and only lambda light chains are identified strongly suggests kappa light chain deficiency.
Further detailed testing is performed when a kappa light chain abnormality is found in immune testing performed for recurrent infections of unknown cause, abnormal serum immunoglobulins, or to exclude hematologic malignancy.
① Kappa light chains not detected or present only in extremely small amounts on serum immunofixation electrophoresis ② Immunoglobulins composed only of lambda light chains replacing all serum immunoglobulins ③ Marked reduction or absence of serum free kappa light chains (sFLC-κ), with an extremely low kappa/lambda sFLC ratio ④ Confirmation of homozygous deletion or a loss-of-function variant of the IGKC gene
IGKC deletion is confirmed by IGKC gene sequencing (Sanger or NGS) or MLPA (Multiple Ligation-dependent Probe Amplification). This distinguishes heterozygous from homozygous deletions to determine clinical significance.
Diseases requiring differentiation include ① kappa monoclonal proliferation (κ chain myeloma, with increased serum kappa light chains and M-protein), ② lambda-predominant polyclonal hypergammaglobulinemia, and ③ multiple myeloma. Monoclonal gammopathies show a selective increase in kappa or lambda light chains, whereas kappa light chain deficiency is characterized by the absence of kappa light chains.
Patients with asymptomatic kappa light chain deficiency are managed without specific treatment, with regular assessment of immune function and follow-up testing of serum immunoglobulins.
When recurrent bacterial infections occur, antibiotic treatment is given during infections, and prophylactic antibiotics are considered if recurrent infections are severe. Vaccinations such as pneumococcal, Hib and meningococcal vaccines are actively given.
The evidence for IVIG treatment in kappa light chain deficiency is insufficient. Commercial IVIG preparations consist of IgG containing both kappa and lambda light chains and do not compensate for the kappa light chain deficiency itself. IVIG administration may be considered only when recurrent invasive infections or functional hypogammaglobulinemia are present.
Regular follow-up for the possible development of hematologic malignancy (serum protein electrophoresis, sFLC testing) is recommended. It is monitored whether an increase in plasma cells bearing only polyclonal λ light chains progresses to lymphoma or myeloma.
Because compensation occurs through lambda light chains in kappa light chain deficiency, many patients show a relatively favorable clinical course. A considerable number of reported cases maintain a normal or near-normal quality of life.
In patients with recurrent infections, infectious complications can be minimized with appropriate vaccination and antibiotic treatment. If recurrent lung infections progress to bronchiectasis, permanent damage to lung function can occur.
The association between kappa light chain deficiency and hematologic malignancy has not been clearly established. However, a theoretical possibility has been raised that immunoglobulin light chain imbalance itself may be associated in the long term with the risk of abnormal plasma cell proliferation (dyscrasias). Regular follow-up testing is needed.
For parents who are carriers of a heterozygous IGKC gene deletion, genetic counseling explains the possibility (25%) of homozygous deletion (kappa light chain deficiency) in their children. Prenatal genetic testing (CVS, amniocentesis) can confirm the fetal genotype.
Pneumococcal (PCV, PPSV23), Hib, meningococcal and influenza vaccination is recommended. Vaccination against encapsulated bacteria is beneficial even in asymptomatic patients.
Changes in clinical status are recognized early through regular follow-up of serum immunoglobulin quantification and the kappa/lambda light chain ratio or sFLC ratio. Serum protein electrophoresis and immunofixation electrophoresis are performed periodically to exclude hematologic malignancy.